IJCEMR

Article http://dx.doi.org/10.26855/ijcemr.2026.09.003

Analysis of Factors Influencing Diabetic Kidney Disease Progression Based on Multidimensional Indicators

TOTAL VIEWS: 392

Mili Shi, Yupin Yang, Jieya Wang, Huan Hu, Qirui Tai*

Department of Pharmacy, Sixth Affiliated Hospital of Kunming Medical University, Yuxi 653100, Yunnan, China.

*Corresponding author: Qirui Tai

Published: September 17,2026

Abstract

Objective: This work pooled evidence gathered from observational cohort investigations alongside randomized controlled trials. We aimed to clarify how demographic traits, laboratory test indices, and anti‑hyperglycemic treatments shape disease advancement among people living with diabetic kidney disease (DKD). Our goal was to deliver practical reference information for early preventive measures and standardized clinical management for patients facing progressive DKD. Methods: Seven major electronic databases were systematically searched to retrieve published studies regarding indicators associated with DKD progression from database inception to December 28, 2025. Validated tools were applied to evaluate the methodological quality of the included studies. Meta-analysis was performed to synthesize two distinct types of hazard ratio (HR) data with corresponding 95% confidence intervals (95% CIs): observational prognostic risk factors derived from cohort studies and therapeutic protective effects obtained from randomized controlled trials (RCTs), which jointly characterize the predictors and modifiable interventions for DKD progression. Results: A total of 43 eligible studies involving 290,469 diabetic patients were included in the quantitative synthesis. Sixteen independent indicators associated with DKD progression were identified and clearly categorized into two subtypes: 11 observational demographic and clinical risk markers from cohort studies, and five pharmacological protective factors validated by RCTs. The pooled HRs of adverse prognostic markers ranged from 1.11 to 3.52, whereas the pooled HRs of renoprotective medications ranged from 0.60 to 0.84. Conclusions: This study identified 16 independent indicators related to DKD progression. Observational demographic and laboratory markers serve as adverse prognostic factors that increase the risk of DKD deterioration. In contrast, pharmacological interventions including sodium-glucose cotransporter 2 inhibitors (SGLT-2i), glucagon-like peptide-1 receptor agonists (GLP-1RAs), dipeptidyl peptidase-4 inhibitors (DPP-4i), metformin, and finerenone exert significant protective effects against DKD progression. The clear distinction between baseline risk predictors and treatment effects provides reliable evidence for clinicians to conduct early risk screening and implement individualized therapeutic strategies for DKD prevention and management.

Keywords

Diabetes mellitus; diabetic kidney disease; delay disease progression

References

[1] Dong W, Wan EYF, Fong DYT, Kwok RLP, Chao DVK, Tan KCB, et al. Prediction models and nomograms for 10-year risk of end-stage renal disease in Chinese type 2 diabetes mellitus patients in primary care. Diabetes Obes Metab. 2021;23(4):897-909.

[2] Boulton AJM, Vileikyte L, Ragnarson-Tennvall G, Apelqvist J. The global burden of diabetic foot disease. Lancet. 2005;366 (9498):1719-24.

[3] Gu L-B, Lou Q-L, Wu H-D, Ouyang X-J, Bian R-W. Lack of association between anemia and renal disease progression in Chi-nese patients with type 2 diabetes. J Diabetes Investig. 2016;7(1):42-7.  

[4] Li Y-J, Hu Y, Huyan X-Y, Chen K, Li B, Gu W-J, et al. Comparison of efficacy and safety of three novel hypoglycemic agents in patients with severe diabetic kidney disease: a systematic review and network meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2022;13:1003263.

[5] Alvarez ML, Al-Rubeaan K, Youssef AM, Subhani SN, Ahmad NA, Al-Sharqawi AH, et al. Diabetic nephropathy and its risk factors in a society with a type 2 diabetes epidemic: a Saudi national diabetes registry-based study. PLoS One. 2014;9(2):e88956.    

[6] Viswanathan V, Tilak P, Kumpatla S. Risk factors associated with the development of overt nephropathy in type 2 diabetes patients: a 12 years observational study. Indian J Med Res. 2012;136(1):46-53.

[7] Huang GM, Huang KY, Lee TY, Weng JTY. An interpretable rule-based diagnostic classification of diabetic nephropathy among type 2 diabetes patients. BMC Bioinformatics. 2015;16(S1):S5.    

[8] Slieker RC, van der Heijden A, Siddiqui MK, Langendoen-Gort M, Nijpels G, Herings R, et al. Performance of prediction models for nephropathy in people with type 2 diabetes: systematic review and external validation study. BMJ. 2021;374:n2134.

[9] Jiang G, Hu C, Tam CHT, Lau ESH, Wang Y, Luk AOY, et al. Genetic and clinical variables identify predictors for chronic kidney disease in type 2 diabetes. Kidney Int. 2016;89(2):411-20.    

[10] Yang XL, So WY, Kong APS, Clarke P, Ho CS, Lam CWK, et al. End-stage renal disease risk equations for Hong Kong Chinese patients with type 2 diabetes: Hong Kong Diabetes Registry. Diabetologia. 2006;49(10):2299-308.

[11] Clarke PM, Gray AM, Briggs A, Farmer AJ, Fenn P, Stevens RJ, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia. 2004;47(10):1747-59.    

[12] DCCT/EDIC Research Group. Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study. Lancet Diabetes Endocrinol. 2014;2(10):793-800.

[13] Humphrey LL, Ballard DJ, Frohnert PP, Chu CP, O'Fallon WM, Palumbo PJ. Chronic renal failure in non-insulin-dependent diabetes mellitus. A population-based study in Rochester, Minnesota. Ann Intern Med. 1989;111(10):788-96.    

[14] Lee ET, Lee VS, Lu M, Lee JS, Russell D, Yeh J. Incidence of renal failure in NIDDM. The Oklahoma Indian Diabetes Study. Diabetes. 1994;43(4):572-9.

[15] Keane WF, Brenner BM, de Zeeuw D, Grunfeld JP, McGill J, Mitch WE, et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int. 2003;63(4):1499-507.    

[16] Ahmed MA, Kishore G, Khader HA, Kasturirangan MN. Risk factors and management of diabetic nephropathy. Saudi J Kidney Dis Transpl. 2013;24(6):1242-7.

[17] Dyck RF, Jiang Y, Osgood ND. The long-term risks of end stage renal disease and mortality among First Nations and non-First Nations people with youth-onset diabetes. Can J Diabetes. 2014;38(4):237-43.

[18] Chang PY, Chien LN, Lin YF, Chiou HY, Chiu WT. Nonadherence of oral antihyperglycemic medication will increase risk of end-stage renal disease. Medicine (Baltimore). 2015;94(47):e2051.   

[19] Burdmann EA, Li HY, Lin HA, Nien FJ, Wu VC, Jiang YD, et al. Serum vascular adhesion protein-1 predicts end-stage renal disease in patients with type 2 diabetes. PLoS One. 2016;11(2):e0147981.

[20] Satirapoj B, Pooluea P, Nata N, Supasyndh O. Urinary biomarkers of tubular injury to predict renal progression and end stage renal disease in type 2 diabetes mellitus with advanced nephropathy: a prospective cohort study. J Diabetes Complications. 2019; 33(9):675-81.    

[21] de Hauteclocque A, Ragot S, Slaoui Y, Gand E, Miot A, Sosner P, et al. The influence of sex on renal function decline in people with type 2 diabetes. Diabet Med. 2014;31(9):1121-8.

[22] Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017;377(9):839-48.    

[23] Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383(15):1425-35.

[24] Neuen BL, Ohkuma T, Neal B, Matthews DR, de Zeeuw D, Mahaffey KW, et al. Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function. Circulation. 2018;138(15):1537-50.    

[25] Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021;384(2):129-39.

[26] Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323-34.    

[27] Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Erondu N, Shaw W, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol. 2018;6(9):691-704.

[28] Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347-57.    

[29] Wanner C, Inzucchi SE, Zinman B, Koitka-Weber A, Mattheus M, George JT, et al. Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: insights from the EMPA-REG OUTCOME trial. Diabetes Obes Metab. 2020;22(12):2335-47.

[30] Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436-46.

[31] Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet. 2019;394(10193):131-8.    

[32] Lin Y, Wang T-H, Tsai M-L, Wu VC-C, Tseng C-J, Lin M-S, et al. The cardiovascular and renal effects of glucagon-like peptide 1 receptor agonists in patients with advanced diabetic kidney disease. Cardiovasc Diabetol. 2023;22(1):60.

[33] Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109-21.    

[34] Schechter M, Melzer Cohen C, Fishkin A, Rozenberg A, Yanuv I, Sehtman-Shachar DR, et al. Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence. Cardiovasc Diabetol. 2023;22(1):126.

[35] Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med. 2021;385(10):896-907.    

[36] Chen CY, Wu VC, Lin CJ, et al. Improvement in mortality and end-stage renal disease in patients with type 2 diabetes after acute kidney injury who are prescribed dipeptidyl peptidase-4 inhibitors. Mayo Clin Proc. 2018;93(12):1760-74.

[37] Chao C-T, Wang J, Wu H-Y, Chien K-L, Hung K-Y. Dipeptidyl peptidase 4 inhibitor use is associated with a lower risk of incident acute kidney injury in patients with diabetes. Oncotarget. 2017;8(32):53028-40.    

[38] Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019;321(1):69-79.

[39] Inagaki N, Yang W, Watada H, Ji L, Schnaidt S, Pfarr E, et al. Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA® trial. Di-abetol Int. 2020;11:129-41.    

[40] Yang A, Lau ESH, Wu HJ, Ma RCW, Kong APS, So WY, et al. Attenuated risk association of end-stage kidney disease with metformin in type 2 diabetes with eGFR categories 1-4. Pharmaceuticals (Basel). 2022;15(9):1140.

[41] Kwon S, Kim YC, Park JY, Lee J, An JN, Kim CT, et al. The long-term effects of metformin on patients with type 2 diabetic kidney disease. Diabetes Care. 2020;43(5):948-55.    

[42] Hung AM, Hackstadt AJ, Griffin MR, Grijalva CG, Greevy RA Jr, Roumie CL. Comparative effectiveness of metformin versus sulfonylureas on kidney function decline or death among patients with reduced kidney function: a retrospective cohort study. CMAJ Open. 2023;11(1):E77-89.

[43] Hung SC, Chang YK, Liu JS, Kuo KL, Chen YH, Hsu CC, et al. Metformin use and mortality in patients with advanced chronic kidney disease: national, retrospective, observational, cohort study. Lancet Diabetes Endocrinol. 2015;3(8):605-14.

[44] Kim MH, Oh HJ, Kwon SH, Jeon JS, Noh H, Han DC, et al. Metformin use and cardiovascular outcomes in patients with diabetes and chronic kidney disease: a nationwide cohort study. Kidney Res Clin Pract. 2021;40(4):660-72.

[45] Charytan DM, Solomon SD, Ivanovich P, Remuzzi G, Cooper ME, McGill JB, et al. Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2019;21(5):1199-208.    

[46] Wan EYF, Fong DYT, Fung CSC, Yu EYT, Chin WY, Chan AKC, et al. Prediction of new onset of end stage renal disease in Chinese patients with type 2 diabetes mellitus - a population-based retrospective cohort study. BMC Nephrol. 2017;18(1):257.

[47] Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295-306.    

[48] Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy. JAMA. 2015;314(9):884-94.

[49] Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219-29.        

[50] Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385(24):2252-63.

[51] Ruilope LM, Pitt B, Anker SD, Rossing P, Kovesdy CP, Pecoits-Filho R, et al. Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study. Nephrol Dial Transplant. 2023;38(2):372-83.    

[52] Raile K, Galler A, Hofer S, Herbst A, Dunstheimer D, Busch P, et al. Diabetic nephropathy in 27,805 children, adolescents, and adults with type 1 diabetes: effect of diabetes duration, A1C, hypertension, dyslipidemia, diabetes onset, and sex. Diabetes Care. 2007;30(10):2523-8.

[53] Elendu C, John Okah M, Fiemotongha KDJ, Adeyemo BI, Bassey BN, Omeludike EK, et al. Comprehensive advancements in the prevention and treatment of diabetic nephropathy: a narrative review. Medicine (Baltimore). 2023;102(40):e35397.

[54] Shepler B, Nash C, Smith C, Dimarco A, Petty J, Szewciw S. Update on potential drugs for the treatment of diabetic kidney disease. Clin Ther. 2012;34(6):1237-46.

[55] Heerspink HJ, De Zeeuw D. Novel anti-inflammatory drugs for the treatment of diabetic kidney disease. Diabetologia. 2016;59(8): 1621-3.    

[56] Lacava V, Pellicanò V, Ferrajolo C, Cernaro V, Visconti L, Conti G, et al. Novel avenues for treating diabetic nephropathy: new investigational drugs. Expert Opin Investig Drugs. 2017;26(4):445-62.

[57] Andrade Lopes S, Jornayvaz FR, De Seigneux S. [Chronic kidney disease and new antidiabetic drugs: an overview in 2019]. Rev Med Suisse. 2019;15(653):1106-11.    

[58] Sattar N, Lee MMY, Kristensen SL, Branch KRH, Del Prato S, Khurmi NS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9(10):653-62.

[59] Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Am J Kidney Dis. 2014;64(4):510-33.

[60] Neugarten J, Golestaneh L. Gender and the prevalence and progression of renal disease. Adv Chronic Kidney Dis. 2013;20(5): 390-5.    

[61] Silbiger SR. Raging hormones: gender and renal disease. Kidney Int. 2011;79(4):382-4.

[62] Burrows NR, Li Y, Geiss LS. Incidence of treatment for end-stage renal disease among individuals with diabetes in the U.S. continues to decline. Diabetes Care. 2010;33(1):73-7.    

[63] Denic A, Glassock RJ, Rule AD. Structural and functional changes with the aging kidney. Adv Chronic Kidney Dis. 2016;23(1): 19-28.

[64] Han JJ, Wu D, Chen ZS, Xiao Y, Sen G. Nomogram-based prediction model for risk of diabetic kidney disease in patients with type 2 diabetes mellitus: development and validation. Chinese General Practice. 2024;27(09):1054-61.    

[65] Man REK, Gan ATL, Fenwick EK, Gupta P, Wong MYZ, Wong TY, et al. The relationship between generalized and abdominal obesity with diabetic kidney disease in type 2 diabetes: a multiethnic Asian study and meta-analysis. Nutrients. 2018;10(11):1685.

[66] Sawicki PT, Didjurgeit U, Mühlhauser I, Bender R, Heinemann L, Berger M. Smoking is associated with progression of diabetic nephropathy. Diabetes Care. 1994;17(2):126-31.    

[67] Yun KJ, Kim HJ, Kim MK, Kwon HS, Baek KH, Roh YJ, et al. Risk factors for the development and progression of diabetic kidney disease in patients with type 2 diabetes mellitus and advanced diabetic retinopathy. Diabetes Metab J. 2016;40(6):473-81.

[68] Fagerudd JA, Tarnow L, Jacobsen P, Stenman S, Nielsen FS, Pettersson-Fernholm KJ, et al. Predisposition to essential hypertension and development of diabetic nephropathy in IDDM patients. Diabetes. 1998;47(3):439-44.    

[69] UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-53.

[70] Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes. 2006;55(6):1832-9.    

[71] Babazono T, Nyumura I, Toya K, Hayashi T, Ohta M, Suzuki K, et al. Higher levels of urinary albumin excretion within the normal range predict faster decline in glomerular filtration rate in diabetic patients. Diabetes Care. 2009;32(8):1518-20.

[72] Grams ME, Garg AX, Lentine KL. Kidney-failure risk projection for the living kidney-donor candidate. N Engl J Med. 2016; 374(21):2094-5.    

How to cite this paper

Analysis of Factors Influencing Diabetic Kidney Disease Progression Based on Multidimensional Indicators

How to cite this paper: Mili Shi, Yupin Yang, Jieya Wang, Huan Hu, Qirui Tai. (2026) Analysis of Factors Influencing Diabetic Kidney Disease Progression Based on Multidimensional Indicators. International Journal of Clinical and Experimental Medicine Research, 10(5), 359-371.

DOI: http://dx.doi.org/10.26855/ijcemr.2026.09.003